BCP and the ECS: Research in Metabolic Signaling
Updated: Oct 19
Part 2 of a 3-Part Series on BCP, OEA, and Your Body’s Natural Path to Metabolic Health
In Part One of this series, we delved into the fascinating nature of the human ECS, discovered in the 1990s. The ECS is proving to be an amazing new frontier for healthcare benefits that are available through no other avenue. BCP activates CB2, a receptor within the ECS.
What Exactly Is BCP?
BCP interacts with CB2, a receptor within the ECS.
Unlike THC, BCP doesn’t act on CB1 receptors and has no psychoactive effects.Instead, it activates CB2 receptors, which are crucial for immune and metabolic function.
What Is the ECS?
As discussed in Part One, your body has an internal regulatory system called the ECS (ECS). This system helps maintain homeostasis — or internal balance — across various functions, including inflammation, pain, stress response, and metabolism.
The ECS Has Two Main Types of Receptors:
CB1 receptors:Primarily located in the brain and nervous system.
CB2 receptors:Found in immune tissues, the gastrointestinal tract, liver, pancreas, and fat cells.
Research on BCP includes CB2, immune, and metabolic signaling.
BCP’s Role in Metabolic Health
Let’s break down the research on what BCP can do for metabolic health:
Research examines relationships among CB2 signaling, inflammatory pathways, and metabolic biology.
Glucose tolerance is one metabolic measure examined in BCP research.
Lipid markers including LDL and triglycerides have been examined in BCP research.
GLP-1 signaling is another area examined in BCP research.
Orexin-A is among the signaling molecules examined in metabolic research.
One published study compared BCP and a GLP-1–based intervention using metabolic measures including body weight and fat mass.
BCP and Inflammatory Signaling
Inflammation is a significant underlying cause of poor metabolic health. It disrupts insulin signaling, interferes with hunger cues, and contributes to fat storage, particularly around the liver and abdomen.
Research examines BCP alongside cytokine and metabolic signaling.
Why We Use Nano BCP
Not all BCP is created equal. Because it’s a plant oil, BCP can be challenging for the body to absorb efficiently in its natural form. That’s why our BCPlus Metabolic Blend uses nano-emulsified BCP. This means the compound is broken into ultra-tiny particles that pass more easily through the intestinal wall and into your bloodstream.
We also utilize enteric-coated capsules, which dissolve more slowly and deliver the ingredients precisely where they’re needed.
The Formula We Trust: BCPlus Metabolic Blend
At Blair Medical Group, we developed a physician-formulated supplement that combines these two compounds in a convenient capsule. Our blend offers optimal bioavailability:
Nano-formulated BCP for better absorption
OEA blend encapsulated in an enteric-coated product to reduce gastric irritation and slowly release the ingredients.
A stimulant-free, clinically thoughtful approach to metabolic health
Want the Full Research?
This blog series offers a high-level overview. For clinicians or science-forward readers, we’ve compiled a more in-depth clinical guide. It includes study references, molecular pathways, and additional data on how these compounds work. See the White Paper offer at right, andCLICK HEREto read and download.
Conclusion
In conclusion, understanding the role of BCP in metabolic health is crucial. The evidence shows that it can significantly impact inflammation and metabolic regulation. As we continue to explore the benefits of BCP, we invite you to consider how it may fit into your wellness journey.
In Part 3,our third and final post in this series, we’ll explore how OEA influences appetite hormones, supports fat oxidation, and helps manage food cravings.
Research references
Gertsch et al. (2008): BCP and CB2 receptor activity. Receptor, cell and mouse experiments identified beta-caryophyllene as a selective CB2 agonist and examined its activity in inflammatory signaling.
Mani et al. (2021): BCP and muscle insulin signaling. A high-fat-diet and fructose-induced diabetic rat study examined BCP alongside skeletal-muscle insulin signaling and glucose-regulation measures.
Alizadeh et al. (2022): BCP and food-addiction scores. An eight-week randomized trial in women with obesity and food-addiction symptoms tested 100 mg BCP daily. Food-addiction scores improved relative to placebo; appetite, body-composition and anthropometric outcomes showed no significant between-group differences.
Comments